Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Carcinogen in popular...

    Carcinogen in popular heartburn drug Zantac triggers safety review by European, US regulators

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-09-14T09:15:16+05:30  |  Updated On 16 Aug 2021 5:11 PM IST

    Valisure said in its report that it found the impurity in both Sanofi SA's branded Zantac as well as generic versions of the drug. But the FDA would not confirm in which versions of the drug it had found the impurity, noting that it found quite different - and lower - amounts of NDMA in the drugs.


    U.S: The U.S. and European drug regulators said on Friday they are reviewing the safety of the widely taken heartburn drug ranitidine, commonly known by the brand name Zantac after they found traces of a probable cancer-causing impurity in some versions of the medicine.


    The U.S. Food and Drug Administration said it had found traces of the impurity, called N-nitrosodimethylamine (NDMA), in some of the drugs with ranitidine in them. Both the FDA and the European Medicines Agency said they will review the drug's safety, but neither agency is currently calling for patients to stop taking it.


    The impurity in ranitidine was first flagged to the regulators by Valisure, an online pharmacy that tests the medication it sells for flaws.


    Valisure said in its report that it found the impurity in both Sanofi SA's branded Zantac as well as generic versions of the drug. But the FDA would not confirm in which versions of the drug it had found the impurity, noting that it found quite different - and lower - amounts of NDMA in the drugs.


    David Light, Valisure's chief executive officer, said his company believes that because ranitidine is unstable, the impurity can form on its own, rather than being introduced by problems in the manufacturing process. He said its possible that the impurity has been in the drug for as long as it has been on the market.


    "It seems to be that there's an inherent problem with the drug itself," Light said in an interview. "There's a lot of concerns that, in our mind, justify completely recalling this product."


    The FDA said it has not determined how long the impurity has been present in Zantac.


    Sanofi, whose stock price was little changed, said in a statement that it takes safety seriously and is committed to working with the FDA. It said Zantac meets all specified safety requirements for use in the over-the-counter market.


    NDMA is one of the impurities that has been found in blood pressure and heart failure medicines called Angiotensin II Receptor Blockers (ARBs). Those impurities are believed to have been introduced by recent changes in the manufacturing processes for ARBs.


    Regulators have been recalling those drugs since last year, and the FDA expanded its investigation of the impurities beyond that class of drugs last month.


    Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, said in an interview that regulators around the world were considering requiring new testing during the manufacturing process to reduce contamination of drugs.


    "We're going to have to be more vigilant," Woodcock said. "I think you'll see tests added at the appropriate point during the manufacturing."


    Blood pressure and heart failure medicines such as valsartan, the generic version of Novartis AG's Diovan, have been recalled by drugmakers such as Mylan NV, Teva Pharmaceutical Industries and Novartis' Sandoz, as the drugs have been found to contain probable carcinogens.


    By Michael Erman


    Read Also: GW Pharma cannabis drug Epidiolex wins European panel nod

    angiotensin II receptor blockersarbsblood pressurecancercarcinogenDavid Lightheart failure medicinesheartburn drugsJanet WoodcockMichael ErmanN-nitrosodimethylamineNDMANovartispharmapharma companypharma newsranitidineSandozSanofiZantac
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok